12/3
08:06 am
vvos
Vivos Therapeutics (NASDAQ:VVOS) had its price target lowered by analysts at Ascendiant Capital Markets from $6.50 to $5.50. They now have a "buy" rating on the stock.
Low
Report
Vivos Therapeutics (NASDAQ:VVOS) had its price target lowered by analysts at Ascendiant Capital Markets from $6.50 to $5.50. They now have a "buy" rating on the stock.
12/3
07:57 am
vvos
Vivos Therapeutics (NASDAQ:VVOS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Vivos Therapeutics (NASDAQ:VVOS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/26
08:10 pm
vvos
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... [Yahoo! Finance]
Low
Report
Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... [Yahoo! Finance]
11/19
04:45 pm
vvos
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 [Yahoo! Finance]
Medium
Report
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 [Yahoo! Finance]
11/19
04:20 pm
vvos
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
High
Report
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025
11/19
08:30 am
vvos
Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
Medium
Report
Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call
11/17
08:06 am
vvos
Vivos Therapeutics (NASDAQ:VVOS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
Low
Report
Vivos Therapeutics (NASDAQ:VVOS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
11/4
01:37 pm
vvos
Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
Neutral
Report
Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]
11/4
08:22 am
vvos
Vivos Therapeutics (NASDAQ:VVOS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Vivos Therapeutics (NASDAQ:VVOS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
9/30
08:30 am
vvos
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Medium
Report
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
9/17
08:30 am
vvos
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Medium
Report
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
9/9
08:07 am
vvos
Vivos Therapeutics (NASDAQ:VVOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.20 to $6.50. They now have a "buy" rating on the stock.
Low
Report
Vivos Therapeutics (NASDAQ:VVOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.20 to $6.50. They now have a "buy" rating on the stock.